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A Case of Metastatic Squamous Cell Carcinoma in a Patient with Recessive Dystrophic Epidermolysis Bullosa that was
Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor
Danielle Yeager, MD, Molly Powers, MD, and David M. Ozog, MD
Henry Ford Health System Department of Dermatology

Therapy and Course

Purpose
• Cutaneous squamous cell carcinomas (SCCs) are the
leading cause of death in patients with recessive
dystrophic epidermolysis bullosa (RDEB).
• Management of SCCs in these patients is challenging
with higher rates of recurrence and lymph node
metastases.
• Although surgery is the first-line treatment in the
majority of cases, certain clinical situations, such as
regional recurrence or distant metastasis, may call for
nonsurgical treatment such as chemotherapy,
immunotherapy, or radiation.
• We report the complex management of SCCs in a
young female patient with RDEB whose nodal disease
responded successfully to the programmed cell death
protein 1 (PD-1) inhibitor, pembrolizumab.

Case
• Patient is a 29-year-old female with a long-standing
history of RDEB complicated by multifocal and
recurrent SCC of the skin.
• She initially presented in 2015, at the age of 24, for
SCC of the skin that was treated with a combination of
Mohs micrographic surgery (MMS), wide local
excision, and laser-assisted topical delivery of
aminolevulinic acid.
• Over the next 6 months, she continued to develop
several additional invasive SCCs.
• Computed tomography (CT) scan revealed bilateral
pulmonary nodules and axillary nodes concerning for
early metastatic disease.
• Left axillary node biopsy performed was negative for
metastatic disease, and these were thought to be
consistent with a reactive process.

Summary

• Oncology recommended off-label palliative use of cetuximab given her multifocal disease and higher risk • Pembrolizumab was the first PD-1 inhibitor
of metastasis in RDEB patients.
approved by the Food and Drug
• She completed 4 cycles of cetuximab complicated by sepsis, likely from a cutaneous source, as well as a
Adminstration (FDA) for metastatic
grade 2 EGFR-associated acneiform eruption.
melanoma.
• After 4 cycles, her CT remained stable, and there was no evidence of cutaneous recurrence
• Recently in clinical trials, a new PD-1
• The decision was made to discontinue cetuximab.
inhibitor cemiplimab showed a 50%
• However, 2 years following the cessation of cetuximab she developed multiple cutaneous recurrences and
response rate (either partial or complete) in
a surveillance CT scan showed enlargement of her left axillary lymph nodes to a mass of 3.7 x 4.0 cm in
the treatment of cutaneous SCC and became
size.
the first systemic drug in its class to be
• Nodal biopsy revealed metastatic SCC and molecular testing performed showed that 100% of tumor cells
approved for the treatment of locally
(tumor proportion score) were positive for PD-L1 staining.
advanced or metastatic cutaneous SCC.
• The decision was made to start pembrolizumab as off-label therapy with plans to pursue axillary node
• We report the first case of metastatic SCC in
excision after she completed treatment.
a RDEB patient that responded to treatment
• At the completion of these 4 cycles, a repeat CT scan showed improvement in the enlarged nodes with
with the PD-1 inhibitor, pembrolizumab.
reduction to 2.2 x 1.4 cm in size.
• Regional lymph node resection was then successfully performed 4 months after her last infusion.
Conclusion
• Pathology of the excised lymph nodes revealed only keratinaceous material without definitive malignant
• Immunotherapy with PD-1 inhibitors, such
cells indicative of her therapeutic response. (Figure 1)
as pembrolizumab, may be an additional
• Long term longitudinal follow up is still required to determine durability of her clinical response.
treatment modality for SCC in RDEB
Histopathology
patients with late stage or metastatic
disease.
• Further larger scale studies are warranted to
determine the utility of PD-1 inhibitors in
the multimodal management of these highrisk patients.
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